The EU Ozempic probe is expanding. What you should know
Global News
The agency began its review after Iceland's health regulator flagged reports of patients thinking about suicide and one case of thoughts of self harm after use of Novo's drugs.
The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk’s NOVOb.CO diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class.
The agency began its review on July 3 after Iceland’s health regulator flagged the reports of patients thinking about suicide and one case of thoughts of self harm after use of Novo’s drugs.
There have been issues of suicidal thoughts linked to another class of weight-loss drugs, which have hobbled previous attempts by the drug industry to develop lucrative weight-loss drugs.
Sanofi’s weight-loss drug Acomplia, which never won U.S. approval, was withdrawn in Europe in 2008 after being linked to suicidal thoughts.
The EMA said on Tuesday it will now investigate the class of drugs known as GLP-1 receptor agonists, which trigger a feeling of fullness after eating. The review is expected to complete in November, according to the agency.
Drugmaker Eli Lilly’s LLY.N shares closed down 3.1%. Its diabetes drug Trulicity also belongs to the same class.
Novo’s weight-loss drug Wegovy, which contains active ingredient semaglutide, is also part of the review.
Other GLP-1 drugs include Sanofi’s SASY.PA Suliqua and AstraZeneca’s AZN.L Bydureon. Both are approved in Europe for treatment of type 2 diabetes.